Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...

The best out-of-the-box tricks to treat atopic dermatitis (eczema), according to expert dermatologists, plus products to try.

Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic dermatitis and delves into each option ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...